Table 2

GOING-FWD cost-sensitive and patient-relevant outcomes measures—wish list

ConditionSurvivalAcute complicationsPatient-reported health statusDisease progressionDisease-specific outcomesMedications
Acute coronary syndromeAll-cause mortalityMajor procedural complicationsSAQ-7
PHQ-2
Revascularisation
Hospitalisation
MI
HF
Stroke
Beta-blockers
ACEi/ARB
Statin
Antiplatelet
Heart failureAll-cause mortalityTreatment side effects/ complicationsKCCQHospitalisationBeta-blockers
ACEi/ARB
MRAs
ARNi
StrokeAll-cause mortalityIntracranial haemorrhageCognitive function
Motor function
Social function
PROMIS SF V.1.1 Global Health
HospitalisationStroke recurrence
DementiaAll-cause mortalityNPI
MoCA
EQ-5D
Bristol Activity Daily Living Scale
QoL-AD
Quality of Well-being Scale
Clinical Dementia Rating
Hospitalisation
Falls
Parkinson’sAll-cause mortalityPDQ-8Hospitalisation
Falls
Multiple SclerosisAll-cause mortalityRelapse
motor/sensory function
Endocrine/
Diabetes
All-cause mortalityKetoacidosis
Hypoglycaemic/ hyperglycaemic
WHO-5
PAID
PHQ-9
Physician visits
Hospitalisation
Microvascular/microvascular complications
Chronic Kidney DiseaseAll-cause mortalityAccess bleeding
Access hematoma
Access infection
Line sepsis
Catheter-related infections
herniation/effusion
SF-12 or
SF-36
PROMIS-Global Health or WHO-5 Global Health
PROMIS-29
EQ-5D-L
PGI
Hospitalisation eGFR
Transplant
Dialysis
Microalbuminuria
Kidney Failure Risk Index
Stage 5
CV events: HF, stroke, MI, PAD
Peritoneal dialysis modality survival/vascular access survival
Graft failure
Activated vitamin D
Erythropoietin
Calcitonin phosphate binders
Potassium binders
Insulin
Statins
MRAs
ACEi/ARB
Beta-blockers
Diuretics
  • ACEi, ACE inhibitors; ARB, angiotensin II receptor blockers; ARNi, angiotensin receptor-neprilysin inhibitors; CV, cardiovascular; eGFR, estimated glomerular filtration rate; EQ-5D, European Quality of Life questionnaire-5D; HF, heart failure; KCCQ, Kansas City Cardiomyopathy Questionnaire; MI, myocardial infarction; MoCA, Montreal Cognitive Assessment; MRA, mineralcorticoid receptor antagonist; NPI, neuropsychiatric inventory; PAD, peripheral arterial disease; PAID, Problem Areas in Diabetes Questionnaire; PDQ-8, Parkinson’s Disease Questionnaire-8; PGI, Patient Global Impression Scales; PHQ-2, Public Health Questionnaire-2; PHQ-9, Patient Health Questionnaire-9; PROMIS-Global Health, Patient-Reported Outcomes Measurement Information System; PROMIS-SF, Patient-Reported Outcomes Measurement Information System Short Form; QoL-AD, Quality of Life-Alzheimer’s Disease questionnaire; SAQ-7, Seattle Angina Questionnaire-7; SF-12/16, 12/16 item Short Form survey; WHO-5, WHO-5 Well-Being Index.